Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 EV-to-EBITDA is 6.17 as of Jul. 14, 2026, which is 62% below its 10-year median of 16.32. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $48.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 505 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 75.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, COSMOS Pharmaceutical's enterprise value is $3,226 Mil.
COSMOS Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was $522 Mil. Therefore, COSMOS Pharmaceutical's EV-to-EBITDA for today is 6.17.
The historical rank and industry rank for COSMOS Pharmaceutical's EV-to-EBITDA or its related term are showing as below:
CSMYF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.21 Med: 16.32 Max: 23.83
Current: 6.44
During the past 13 years, the highest EV-to-EBITDA of COSMOS Pharmaceutical was 23.83. The lowest was 6.21. And the median was 16.32.
CSMYF's EV-to-EBITDA is ranked better than 75.05% of 505
companies
in the Healthcare Providers & Services industry
Industry Median: 11.01
vs CSMYF: 6.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
COSMOS Pharmaceutical's PE Ratio (TTM) for today is calculated as:
COSMOS Pharmaceutical's share price for today is $37.06.
COSMOS Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.627.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
COSMOS Pharmaceutical EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's EV-to-EBITDA falls into.
COSMOS Pharmaceutical's current Enterprise Value is $3,226 Mil.
COSMOS Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $522 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a EV-to-EBITDA of 6.17 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on COSMOS Pharmaceutical. This is 62% below median its historical median of 16.32. Over the past decade, COSMOS Pharmaceutical's EV-to-EBITDA has ranged from 6.21 to 23.83. According to the industry distribution chart, COSMOS Pharmaceutical ranks #126 out of 505 companies in the Healthcare Providers & Services industry, placing it in the top 25%.
Is COSMOS Pharmaceutical's EV-to-EBITDA too high?
COSMOS Pharmaceutical's current EV-to-EBITDA of 6.17 is 62% below median its 10-year median of 16.32. Over the past 10 years, this metric has ranged from a low of 6.21 to a high of 23.83. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.01. COSMOS Pharmaceutical's value of 6.17 is 44% below this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #126 out of 505 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #126 out of 505 companies for EV-to-EBITDA. This places COSMOS Pharmaceutical in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 11.01. COSMOS Pharmaceutical's value of 6.17 is 44% below this benchmark. Historically, COSMOS Pharmaceutical's own EV-to-EBITDA has ranged from 6.21 to 23.83 over the past decade. While the company's 10-year median is 16.32 vs. the industry median of 11.01, COSMOS Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.01, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current EV-to-EBITDA of 6.17 is 44% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on COSMOS Pharmaceutical. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current EV-to-EBITDA is 6.17, which is 62% below median its own 10-year median of 16.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $48.99, compared to a current price of $37.06 — trading 24.4% below its estimated fair value. The current EV-to-EBITDA is 6.17, which is 62% below median its 10-year median of 16.32 and 44% below the Healthcare Providers & Services industry median of 11.01. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current EV-to-EBITDA is 6.17 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 24.4% below its estimated GF Value™ of $48.99.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
EV-to-EBITDA: 6.17 (62% below median its 10-year median of 16.32)
GF Value™: $48.99 vs. price of $37.06 (24.4% below fair value)
Industry Position: 44% below the Healthcare Providers & Services median (#126 of 505)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
